![As Advair struggles, GlaxoSmithKline seeks expanded label for blockbuster-to-be Trelegy | Fierce Pharma As Advair struggles, GlaxoSmithKline seeks expanded label for blockbuster-to-be Trelegy | Fierce Pharma](https://qtxasset.com/cdn-cgi/image/w=384,h=216,f=auto,fit=crop,g=0.5x0.5/https://qtxasset.com/quartz/qcloud5/media/image/FiercePharma-1511795226/trelegy.png?VersionId=9ZF.d_etbLV7zCq2is7cCwUDiksDCDFI)
As Advair struggles, GlaxoSmithKline seeks expanded label for blockbuster-to-be Trelegy | Fierce Pharma
![INCRUSE ELLIPTA Loss of Exclusivity (LOE). When will the INCRUSE ELLIPTA patents expire, and when will generic INCRUSE ELLIPTA be available? INCRUSE ELLIPTA Loss of Exclusivity (LOE). When will the INCRUSE ELLIPTA patents expire, and when will generic INCRUSE ELLIPTA be available?](https://www.drugpatentwatch.com/p/graph/s/t/INCRUSE+ELLIPTA-patent-expirations.png)
INCRUSE ELLIPTA Loss of Exclusivity (LOE). When will the INCRUSE ELLIPTA patents expire, and when will generic INCRUSE ELLIPTA be available?
![Incruse Ellipta for the Treatment Chronic Obstructive Pulmonary Disease (COPD) - Clinical Trials Arena Incruse Ellipta for the Treatment Chronic Obstructive Pulmonary Disease (COPD) - Clinical Trials Arena](https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/3l-Image-Umeclidinium.jpg)
Incruse Ellipta for the Treatment Chronic Obstructive Pulmonary Disease (COPD) - Clinical Trials Arena
![Incruse Ellipta for the Treatment Chronic Obstructive Pulmonary Disease (COPD) - Clinical Trials Arena Incruse Ellipta for the Treatment Chronic Obstructive Pulmonary Disease (COPD) - Clinical Trials Arena](https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2019/07/2l-Image-Inhaler.jpg)